Impact of a Multimodal Antimicrobial Stewardship Program on Pseudomonas aeruginosa Susceptibility and Antimicrobial Use in the Intensive Care Unit Setting

Table 1

Intensive care unit anti-pseudomonal antibiotic utilization (2003–2010).

	2003	2004	2005	2006	2007	2008	2009	2010
Cefepime	4.5	4.0	18.5	36.5	68.5^†	92.5	36.0	90.5 ^†
Ceftazidime	90.5	62.5	53.0	38.0	24.5	39.0	23.5	25.5
Piperacillin-tazobactam	87.0	124.5	127.5	115.5^†	97.5	139.0	130.0^†	133.0
Carbapenems	30.0	52.5	53.0	60.0	48.5	112. ^†	88.5	78.5
Ciprofloxacin	192.5	148.0	57.8	25.5	40.0	66.5	48.0	87.0
Gentamicin	10.5	20.5	40.0	26.5	8.5	17.5	10.5	11.0
Tobramycin	1.0	0.5	42.5	56.5	58.0	48.0	35.0	31.0

Data expressed as defined daily dose (DDD) per 1000 patient-days.
The two years with the highest percentage of specific antibiotic use are bolded.
^†Year with two cycles of this antibiotic in VAP protocol.